{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:58:16Z","timestamp":1788235096135,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-025-01955-3","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:03:50Z","timestamp":1742191430000},"page":"912-926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug\u2013Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Simon","family":"D\u00f6hrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Borchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Amundson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Almaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Abelovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvir","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Zuill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Dedeic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grayson","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Donatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Haussener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Noncovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Balkovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Bensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-0828","authenticated-orcid":false,"given":"Jeffrey B.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-9301","authenticated-orcid":false,"given":"Shawn","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8621-3299","authenticated-orcid":false,"given":"Leslie W.","family":"Tari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"1955_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. Influenza. Nat. Rev. Dis. Primers 4, 3 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1955_CR2","doi-asserted-by":"publisher","unstructured":"Krammer, F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio https:\/\/doi.org\/10.1128\/mBio.02332-17 (2018).","DOI":"10.1128\/mBio.02332-17"},{"key":"1955_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1955_CR4","doi-asserted-by":"publisher","first-page":"20248","DOI":"10.1073\/pnas.1320524110","volume":"110","author":"NS Heaton","year":"2013","unstructured":"Heaton, N. S., Sachs, D., Chen, C. J., Hai, R. & Palese, P. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc. Natl Acad. Sci. USA 110, 20248\u201320253 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1955_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","volume":"166","author":"NL Kallewaard","year":"2016","unstructured":"Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166, 596\u2013608 (2016).","journal-title":"Cell"},{"key":"1955_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1204839","volume":"333","author":"DC Ekiert","year":"2011","unstructured":"Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843\u2013850 (2011).","journal-title":"Science"},{"key":"1955_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"1955_CR8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.3390\/v6062465","volume":"6","author":"TJ Wohlbold","year":"2014","unstructured":"Wohlbold, T. J. & Krammer, F. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6, 2465\u20132494 (2014).","journal-title":"Viruses"},{"key":"1955_CR9","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1093\/infdis\/jiz017","volume":"219","author":"MC Eichelberger","year":"2019","unstructured":"Eichelberger, M. C. & Monto, A. S. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J. Infect. Dis. 219, S75\u2013S80 (2019).","journal-title":"J. Infect. Dis."},{"key":"1955_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/j.1460-2075.1992.tb05026.x","volume":"11","author":"WP Burmeister","year":"1992","unstructured":"Burmeister, W. P., Ruigrok, R. W. & Cusack, S. The 2.2\u2009A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11, 49\u201356 (1992).","journal-title":"EMBO J."},{"key":"1955_CR11","doi-asserted-by":"publisher","first-page":"20748","DOI":"10.1073\/pnas.1113801108","volume":"108","author":"MR Sandbulte","year":"2011","unstructured":"Sandbulte, M. R. et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl Acad. Sci. USA 108, 20748\u201320753 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1955_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1073\/pnas.87.2.786","volume":"87","author":"ED Kilbourne","year":"1990","unstructured":"Kilbourne, E. D., Johansson, B. E. & Grajower, B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA 87, 786\u2013790 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1955_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"1955_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1074\/jbc.M411506200","volume":"280","author":"LM Chavas","year":"2005","unstructured":"Chavas, L. M. et al. Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition. J. Biol. Chem. 280, 469\u2013475 (2005).","journal-title":"J. Biol. Chem."},{"key":"1955_CR15","doi-asserted-by":"publisher","first-page":"199039","DOI":"10.1016\/j.virusres.2023.199039","volume":"325","author":"PJ Yates","year":"2023","unstructured":"Yates, P. J. et al. Lessons from resistance analysis in clinical trials of IV zanamivir. Virus Res. 325, 199039 (2023).","journal-title":"Virus Res."},{"key":"1955_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/363418a0","volume":"363","author":"M von Itzstein","year":"1993","unstructured":"von Itzstein, M. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418\u2013423 (1993).","journal-title":"Nature"},{"key":"1955_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1021\/ja963036t","volume":"119","author":"CU Kim","year":"1997","unstructured":"Kim, C. U. et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681\u2013690 (1997).","journal-title":"J. Am. Chem. Soc."},{"key":"1955_CR18","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1021\/jm0002679","volume":"43","author":"YS Babu","year":"2000","unstructured":"Babu, Y. S. et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43, 3482\u20133486 (2000).","journal-title":"J. Med. Chem."},{"key":"1955_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1473-3099(09)70199-9","volume":"9","author":"J Burch","year":"2009","unstructured":"Burch, J. et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect. Dis. 9, 537\u2013545 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"1955_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","volume":"5","author":"FM Marty","year":"2017","unstructured":"Marty, F. M. et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir. Med. 5, 135\u2013146 (2017).","journal-title":"Lancet Respir. Med."},{"key":"1955_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/nature06956","volume":"453","author":"PJ Collins","year":"2008","unstructured":"Collins, P. J. et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453, 1258\u20131261 (2008).","journal-title":"Nature"},{"key":"1955_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3851\/IMP2067","volume":"17","author":"HT Nguyen","year":"2012","unstructured":"Nguyen, H. T., Fry, A. M. & Gubareva, L. V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther. 17, 159\u2013173 (2012).","journal-title":"Antivir. Ther."},{"key":"1955_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden, F. G. et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 379, 913\u2013923 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1955_CR24","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1073\/pnas.1002123107","volume":"107","author":"LJ Calder","year":"2010","unstructured":"Calder, L. J., Wasilewski, S., Berriman, J. A. & Rosenthal, P. B. Structural organization of a filamentous influenza A virus. Proc. Natl Acad. Sci. USA 107, 10685\u201310690 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1955_CR25","doi-asserted-by":"publisher","first-page":"19123","DOI":"10.1073\/pnas.0607614103","volume":"103","author":"A Harris","year":"2006","unstructured":"Harris, A. et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl Acad. Sci. USA 103, 19123\u201319127 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1955_CR26","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1128\/AAC.48.12.4542-4549.2004","volume":"48","author":"SJ Macdonald","year":"2004","unstructured":"Macdonald, S. J. et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob. Agents Chemother. 48, 4542\u20134549 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1955_CR27","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1093\/jac\/dku127","volume":"69","author":"EB Tarbet","year":"2014","unstructured":"Tarbet, E. B. et al. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses. J. Antimicrob. Chemother. 69, 2164\u20132174 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"1955_CR28","doi-asserted-by":"publisher","first-page":"6303","DOI":"10.1021\/acs.jmedchem.6b00537","volume":"59","author":"L Fu","year":"2016","unstructured":"Fu, L. et al. Structure-based tetravalent zanamivir with potent inhibitory activity against drug-resistant influenza viruses. J. Med. Chem. 59, 6303\u20136312 (2016).","journal-title":"J. Med. Chem."},{"key":"1955_CR29","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514\u201323524 (2006).","journal-title":"J. Biol. Chem."},{"key":"1955_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7114","volume":"6","author":"H Wan","year":"2015","unstructured":"Wan, H. et al. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Nat. Commun. 6, 6114 (2015).","journal-title":"Nat. Commun."},{"key":"1955_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","volume":"146","author":"LV Gubareva","year":"2017","unstructured":"Gubareva, L. V. et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015\u20132016. Antiviral Res. 146, 12\u201320 (2017).","journal-title":"Antiviral Res."},{"key":"1955_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1080\/07391102.2017.1305295","volume":"36","author":"RS Mandal","year":"2018","unstructured":"Mandal, R. S., Panda, S. & Das, S. In silico prediction of drug resistance due to S247R mutation of influenza H1N1 neuraminidase protein. J. Biomol. Struct. Dyn. 36, 966\u2013980 (2018).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"1955_CR33","unstructured":"Preliminary Estimated Flu Disease Burden 2023\u20132024 Flu Season (CDC, 2024)."},{"key":"1955_CR34","doi-asserted-by":"publisher","first-page":"e201323","DOI":"10.1001\/jamanetworkopen.2020.1323","volume":"3","author":"EJ Chow","year":"2020","unstructured":"Chow, E. J. et al. Respiratory and nonrespiratory diagnoses associated with influenza in hospitalized adults. JAMA Netw. Open 3, e201323 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1955_CR35","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/cid\/ciy770","volume":"68","author":"GT Ray","year":"2019","unstructured":"Ray, G. T. et al. Intraseason waning of influenza vaccine effectiveness. Clin. Infect. Dis. 68, 1623\u20131630 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1955_CR36","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1093\/cid\/ciaa340","volume":"71","author":"JI Tokars","year":"2020","unstructured":"Tokars, J. I. et al. Waning of measured influenza vaccine effectiveness over time: the potential contribution of leaky vaccine effect. Clin. Infect. Dis. 71, e633\u2013e641 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1955_CR37","doi-asserted-by":"publisher","first-page":"20786","DOI":"10.1073\/pnas.1909613116","volume":"116","author":"P Sah","year":"2019","unstructured":"Sah, P. et al. Future epidemiological and economic impacts of universal influenza vaccines. Proc. Natl Acad. Sci. USA 116, 20786\u201320792 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1955_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0019-3","volume":"2","author":"G Salazar","year":"2017","unstructured":"Salazar, G., Zhang, N., Fu, T. M. & An, Z. Antibody therapies for the prevention and treatment of viral infections. npj Vaccines 2, 19 (2017).","journal-title":"npj Vaccines"},{"key":"1955_CR39","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis935","volume":"207","author":"RB Couch","year":"2013","unstructured":"Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207, 974\u2013981 (2013).","journal-title":"J. Infect. Dis."},{"key":"1955_CR40","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","volume":"212","author":"AS Monto","year":"2015","unstructured":"Monto, A. S. et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J. Infect. Dis. 212, 1191\u20131199 (2015).","journal-title":"J. Infect. Dis."},{"key":"1955_CR41","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/cid\/ciae368","volume":"79","author":"SK Tan","year":"2024","unstructured":"Tan, S. K. et al. A randomized, placebo-controlled trial to evaluate the safety and efficacy of VIR-2482 in healthy adults for prevention of influenza A illness (PENINSULA). Clin. Infect. Dis. 79, 1054\u20131061 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"1955_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coi.2018.04.002","volume":"53","author":"J Tan","year":"2018","unstructured":"Tan, J., Asthagiri Arunkumar, G. & Krammer, F. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? Curr. Opin. Immunol. 53, 45\u201350 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"1955_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012327118","volume":"118","author":"RK Borchering","year":"2021","unstructured":"Borchering, R. K. et al. Anomalous influenza seasonality in the United States and the emergence of novel influenza B viruses. Proc. Natl Acad. Sci. USA 118, e2012327118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1955_CR44","doi-asserted-by":"publisher","first-page":"e00417-","DOI":"10.1128\/mBio.00417-16","volume":"7","author":"MJ Memoli","year":"2016","unstructured":"Memoli, M. J. et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model. mBio 7, e00417-16 (2016).","journal-title":"mBio"},{"key":"1955_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"YQ Chen","year":"2018","unstructured":"Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429.e10 (2018).","journal-title":"Cell"},{"key":"1955_CR46","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-023-06136-y","volume":"618","author":"C Momont","year":"2023","unstructured":"Momont, C. et al. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature 618, 590\u2013597 (2023).","journal-title":"Nature"},{"key":"1955_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34521-0","volume":"13","author":"A Yasuhara","year":"2022","unstructured":"Yasuhara, A. et al. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat. Commun. 13, 6602 (2022).","journal-title":"Nat. Commun."},{"key":"1955_CR48","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4161\/mabs.25234","volume":"5","author":"PJK van Meer","year":"2013","unstructured":"van Meer, P. J. K. et al. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. mAbs 5, 810\u2013816 (2013).","journal-title":"mAbs"},{"key":"1955_CR49","doi-asserted-by":"publisher","first-page":"e00350-","DOI":"10.1128\/AAC.00350-19","volume":"63","author":"Z Magyarics","year":"2019","unstructured":"Magyarics, Z. et al. Randomized, double-blind, placebo-controlled, single-ascending-dose study of the penetration of a monoclonal antibody combination (ASN100) targeting Staphylococcus aureus cytotoxins in the lung epithelial lining fluid of healthy volunteers. Antimicrob. Agents Chemother. 63, e00350-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1955_CR50","doi-asserted-by":"publisher","first-page":"e0088723","DOI":"10.1128\/mbio.00887-23","volume":"14","author":"R Honce","year":"2023","unstructured":"Honce, R. et al. Efficacy of oseltamivir treatment in influenza virus-infected obese mice. mBio 14, e0088723 (2023).","journal-title":"mBio"},{"key":"1955_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.vaccine.2016.11.060","volume":"35","author":"CA van Baalen","year":"2017","unstructured":"van Baalen, C. A. et al. ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. Vaccine 35, 46\u201352 (2017).","journal-title":"Vaccine"},{"key":"1955_CR52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1743-422X-2-84","volume":"2","author":"E Zielinska","year":"2005","unstructured":"Zielinska, E. et al. Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis. Virol J. 2, 84 (2005).","journal-title":"Virol J"},{"key":"1955_CR53","doi-asserted-by":"publisher","first-page":"10309","DOI":"10.1128\/JVI.01109-09","volume":"83","author":"B Zhou","year":"2009","unstructured":"Zhou, B. et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza A viruses. J. Virol. 83, 10309\u201310313 (2009).","journal-title":"J. Virol."},{"key":"1955_CR54","doi-asserted-by":"crossref","unstructured":"Saphire, E. O. et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293, 1155\u20131159 (2001).","DOI":"10.1126\/science.1061692"},{"key":"1955_CR55","doi-asserted-by":"crossref","unstructured":"Vavricka, C. J. et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group-specific mechanisms for influenza NA inhibition. PLoS Pathog. 7, e1002249 (2011).","DOI":"10.1371\/journal.ppat.1002249"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-01955-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-01955-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-01955-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:31:14Z","timestamp":1743787874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-01955-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["1955"],"URL":"https:\/\/doi.org\/10.1038\/s41564-025-01955-3","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors listed are current or past shareholders and\/or employees of Cidara Therapeutics, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}